相关实验视频
Updated: May 27, 2025

09:41
Performing and Processing FNA of Anterior Fat Pad for Amyloid
Published on: October 30, 2010
55.0K
心脏 Amyloidosis: 在诊断和治疗的创新
Vincenzo Castiglione1,2, Sabrina Montuoro1, Giulia Orlando1
1Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Via Giuseppe Moruzzi 1, Pisa 56124, Italy.
概括
心脏粉症 (CA) 是一种渐进的心脏病. 最近在粉样蛋白轻链 (AL) 和粉样蛋白 (ATTR) CA的诊断和治疗方面的进展为改善检测和新疗法提供了改善.
科学领域:
- 心脏病学 心脏病学
- 生物化学 生物化学
- 医学诊断 医学诊断 医学诊断
背景情况:
- 心脏粉症 (CA) 是一种渐进的,往往被诊断不足的疾病.
- 它是由心脏肌肉中蛋白质沉积的错误折叠造成的,导致心脏功能受损.
- 全球最常见的亚型是粉样蛋白轻链 (AL) 和跨甲基素 (ATTR) CA.
研究的目的:
- 审查最近在心脏粉样性病诊断方面的进展.
- 突出AL-CA和ATTR-CA的新兴和创新的治疗策略.
- 讨论用于改进检测,准确性和非侵入性亚型差异化的新工具.
主要方法:
- 关于CA的诊断工具和治疗干预措施的最新文献的审查.
- 专注于人工智能增强的分析和先进的成像 (例如,PET扫描具有特定的追踪器).
- 审查正在进行的临床试验,针对针对粉样纤维的新疗法,基因沉默和化疗.
主要成果:
- 新型诊断工具,包括人工智能和PET成像,显示了提高检测速率和准确性的潜力.
- 不侵入性分化AL-CA和ATTR-CA的亚型可能会变得更加可行.
- 对AL-CA的抗纤维细胞疗法和对ATTR-CA的基因沉默/抗纤维细胞疗法的有希望的结果正在出现.
结论:
- 诊断技术的进步有望提高早期和准确的心脏粉样性病的鉴定.
- 创新的治疗方法,包括向疗法和基因沉默,为管理和潜在地阻止疾病进展提供了新的希望.
- 改进的诊断和治疗策略对于应对这种渐进的心脏疾病所带来的挑战至关重要.
更多相关视频
相关概念视频
Heart Failure Drugs: Inotropic Agents
499
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
499
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
371
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371

